Stock performance is driven by a range of macroeconomic and microeconomic factors, along with sector-specific parameters. The table below presents illustrative performance data for select recommendations covered during the relevant period. Past performance is neither an indicator nor a guarantee of future performance.
Exemplary Stocks Past Performance (Closed Recommendations)
| Portfolio Name | Company Name | Ticker | Average Buy Price | First Buy Date | Sell Price | Sell Date | Notional Gain/Loss * | Duration Days# |
|---|---|---|---|---|---|---|---|---|
| Sector Report | Pphe Hotel Group Limited | LSE: PPH | GBX 1,604.00 | 1-Apr-26 | GBX 2,090.00 | 28-May-26 | ▲30.30% | 57 |
| AIM Equity Report | Ensilica Plc | LSE: ENSI | GBX 94.00 | 26-May-26 | GBX 120.00 | 27-May-26 | ▲27.66% | 1 |
| HealthCare Report | Advanced Medical Solutions Group Plc | LSE: AMS | GBX 216.00 | 19-Feb-26 | GBX 272.00 | 20-Apr-26 | ▲25.93% | 60 |
| Gold Report | Hochschild Mining Plc | LSE: HOC | GBX 513.50 | 23-Mar-26 | GBX 641.50 | 1-Apr-26 | ▲24.93% | 9 |
| Sector Report | Itm Power Plc | LSE: ITM | GBX 133.70 | 22-Apr-26 | GBX 165.90 | 24-Apr-26 | ▲24.08% | 2 |
| Sector Report | Ceres Power Holdings Plc | LSE: CWR | GBX 634.50 | 20-May-26 | GBX 780.00 | 22-May-26 | ▲22.93% | 2 |
| Resources Report | Altyngold Plc | LSE: ALTN | GBX 1,150.00 | 18-Mar-26 | GBX 1,405.00 | 8-Apr-26 | ▲22.17% | 21 |
| HealthCare Report | Spire Healthcare Group Plc | LSE: SPI | GBX 184.16 | 12-Mar-26 | GBX 215.50 | 14-May-26 | ▲17.02% | 63 |
| AIM Equity Report | Serabi Gold Plc | LSE: SRB | GBX 285.00 | 17-Mar-26 | GBX 330.00 | 8-Apr-26 | ▲15.79% | 22 |
| Sector Report | Goldplat Plc | LSE: GDP | GBX 14.25 | 6-May-26 | GBX 16.50 | 20-May-26 | ▲15.79% | 14 |
| Sector Report | United Utilities Group Plc | LSE: UU | GBX 1,266.00 | 25-Mar-26 | GBX 1,465.50 | 30-Apr-26 | ▲15.76% | 36 |
| HealthCare Report | Rua Life Sciences Plc | LSE: RUA | GBX 12.97 | 26-Mar-26 | GBX 15.00 | 13-Apr-26 | ▲15.65% | 18 |
| Sector Report | Clean Power Hydrogen Plc | LSE: CPH2 | GBX 9.04 | 20-May-26 | GBX 10.45 | 21-May-26 | ▲15.60% | 1 |
| Investor Report | Barclays Plc | LSE: BARC | GBX 382.90 | 9-Mar-26 | GBX 440.50 | 8-Apr-26 | ▲15.04% | 30 |
| Dividend Income Report | British American Tobacco P.L.C. | LSE: BATS | GBX 4,330.00 | 6-Mar-26 | GBX 4,891.00 | 14-May-26 | ▲12.96% | 69 |
| Sector Report | Ceres Power Holdings Plc | LSE: CWR | GBX 434.68 | 22-Apr-26 | GBX 494.20 | 23-Apr-26 | ▲13.69% | 1 |
| Resources Report | Altyngold Plc | LSE: ALTN | GBX 1,110.00 | 29-Apr-26 | GBX 1,260.00 | 8-May-26 | ▲13.51% | 9 |
| Sector Report | Keystone Law Group Plc | LSE: KEYS | GBX 450.00 | 1-Apr-26 | GBX 510.00 | 29-Apr-26 | ▲13.33% | 28 |
| HealthCare Report | Niox Group Plc | LSE: NIOX | GBX 60.89 | 23-Apr-26 | GBX 69.00 | 27-Apr-26 | ▲13.32% | 4 |
| Sector Report | Standard Chartered Plc | LSE: STAN | GBX 1,617.00 | 18-Mar-26 | GBX 1,830.00 | 20-Apr-26 | ▲13.17% | 33 |
| Investor Report | Babcock International Group Plc | LSE: BAB | GBX 1,281.67 | 2-Feb-26 | GBX 1,280.50 | 10-Apr-26 | ▼-0.09% | 67 |
| Technology Report | Kainos Group Plc | LSE: KNOS | GBX 861.25 | 16-Jan-26 | GBX 859.33 | 17-Apr-26 | ▼-0.22% | 91 |
| Dividend Income Report | Associated British Foods Plc | LSE: ABF | GBX 1,942.33 | 5-Dec-25 | GBX 1,931.00 | 5-Feb-26 | ▼-0.58% | 62 |
| Investor Report | Breedon Group Plc | LSE: BREE | GBX 350.84 | 7-Jul-25 | GBX 347.20 | 3-Feb-26 | ▼-1.04% | 211 |
| Inflation Report | Greggs Plc | LSE: GRG | GBX 1,733.62 | 10-Jan-25 | GBX 1,705.00 | 5-Feb-26 | ▼-1.65% | 391 |
| Sector Report | Genuit Group Plc | LSE: GEN | GBX 358.10 | 28-May-25 | GBX 341.50 | 3-Feb-26 | ▼-4.64% | 251 |
Where a stock has been recommended multiple times the average price is taken into consideration. We might need to provide update on a stock several times during a year or for the length of coverage and for that reason the average BUY price is taken into consideration.
Performance figures quoted do not take into account transaction fees and charges. The profits or losses are hypothetical and include dividends or distribution for the length of the coverage until the recommendation is designated as closed.
Our portfolio is hypothetical and our performance figures are based on recommendations from Kalkine Reports using stock prices as at the date of publication.
The above stock performance data is provided for illustrative and informational purposes only and represents a limited subset of Kalkine’s broader research coverage. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. You should make your own enquiries about any investments, and we strongly suggest you seek advice before acting upon any recommendation. All information represents our views at the date of publication and may change without notice. To the extent permitted by law, Kalkine Limited excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine Limited hereby limits its liability, to the extent permitted by law to the resupply of services.